Key Studies Influencing My Practice Following Washington 2017

October 20-24, 2017; Washington, DC
Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed.
Format: Audio (.mp3)
File Size: 46.24 MB
Released: November 20, 2017

Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed. (50 minutes)

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Axcella, Capulus, the Chronic Liver Disease Foundation, Cirius, Genfit, Echosens, Histoindex, Intercept, Madrigal, NGM Bio, Novartis, Novo Nordisk, Perspectum, and Prometheus; has received fees for non-CME/CE services from AbbVie, Alexion, and Gilead Sciences; and has an ownership interest in Cirius.

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and funds for research support from AbbVie and Gilead Sciences.

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Gilead Sciences and Merck and funds for research support from AbbVie, Gilead Sciences, and Merck.

Acknowledgements

Educational grant provided by:
AbbVie
Gilead Sciences
Merck & Co., Inc.

Related Content

Patients with hepatitis B may benefit from peginterferon if they need a limited duration of therapy, have genotype A HBV, or have hepatitis D coinfection.

Robert S. Brown, Jr., MD, MPH Released: May 21, 2018

Expert faculty members summarize key viral hepatitis studies from this important annual conference.

Released: April 30, 2018

Listen to downloadable audio from a live Webinar by Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, in which the clinical impact of new NAFLD/NASH data reported at the Paris meeting is discussed.

Zobair M. Younossi, MD, MPH, FACP, FACG Released: April 30, 2018

Expert faculty summarize key NAFLD/NASH studies presented in Paris.

Released: April 30, 2018

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?